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BACKGROUND: the Eastern mediterranean Bone marrow transplantation (EmBmt) Group has accumulated 
over 25 years of data and experience in hematopoietic stem cell transplantation (hsCt), most particularly in he-
moglobinopathies, severe aplastic anemia (saa), and inherited metabolic and immune disorders, in addition to 
hematologic malignancies peculiar to the region and where recent updates in trends in activities are warranted. 
OBJECTIVES: to study trends in hsCt activities in the World health organization-Eastern mediterranean (Em) 
region surveyed by EmBmt between 2008 and 2009. stuDY DEsiGn: retrospective analysis of the survey 
data, mainly of the cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of 
conditioning as myeloablative (maC) vs. reduced intensity conditioning (riC) and trends in leukemias, hemo-
globinopathies, saa, inherited bone marrow failure syndromes amongst others. 
RESULTS AND DISCUSSION: fourteen teams from ten Eastern mediterranean region organization (Emro) 
countries reported their data (100% return rate) to the EmBmt for the years 2008-2009 with a total of 2608 
first hsCt (1286 in 2008; 1322 in 2009). allogeneic hsCt represented the majority (63%) in both years. the 
main indications for allogeneic hsCt were acute leukemias (732; 44%), bone marrow failure syndromes (331, 
20%), hemoglobinopathies (255; 15%) and immune deficiencies (90; 5%). there was a progressive increase in 
the proportions of chronic myeloid leukemia (CmL) cases transplanted beyond the first chronic phase (3; 7% of 
all CmL cases in 2008 vs 13; 29% in 2009). the main indications for autologous transplants were plasma cell 
disorders (345; 36%) hodgkin disease (256; 27%), non-hodgkin lymphoma (207; 22%) and solid tumors (83; 
9%). riC continued to show a progressive increase over the years (7% in 2007, 11% in 2008 and 13% in 2009), 
yet remained relatively low compared to contemporary practices in Europe published by EBmt. the vast major-
ity (95%) of allo-hsCt sources were from sibling donors with a continued dominance of peripheral blood (PB) 
(1076; 63%), while cord blood transplant (CBt) increased to 83 (5% of allo-hsCt), matched unrelated donor 
(muD) remained underutilized (1; 0%) and there were no haploidentical transplants reported. Large centers 
with >50 hsCt/year showed a plateau of the total number of allo-hsCt over the last 5 years that may be related 
special report HSCT IN EMRO
Hematol Oncol Stem Cell Ther 4(2)     Second Quarter 2011 hemoncstem.edmgr.com82
to capacity issues and needs further study. 
CONCLUSIONS AND RECOMMENDATIONS: there is an overall increased rate of hsCt in the Emro region 
with a significant increase in utilization of CBt and allogeneic PB-hsCt as a valuable source. however, further 
research on outcome data and development of regional donor banks (CB and muD) may help facilitate future 
planning to satisfy the regional needs and increase collaboration within the group and globally.
Hematopoietic stem cell transplantation (HSCT) has become an important and well established curative procedure for many cont
genital and acquired disorders of the hematopoietic 
system. Annual reports from various HSCT groups 
and registries like European Bone Marrow Transplant 
(EBMT), International Bone Marrow Transplant 
Registry (IBMTR), World Bone Marrow Transplant 
(WBMT) and AsiatPacific Bone Marrow Transplant 
(APBMT) groups have become important instruments 
to describe the status of hematopoietic SCT in differt
ent regions, to observe trends and to monitor the techt
nology used.1t7
EMBMT is a relatively new group that was estabt
lished in 2007 after a number of meetings between 
transplant teams from the WHO EMRO region,8 with 
the aim of sharing experience, initiation of collaborative 
trials and the establishment of common strategies for 
transplantation, taking into consideration the specific 
issues and peculiarities relevant to the region.9 
Although many of the included teams also report 
to and exchange experience with other international 
registries, like EBMT and IBMTR, their data may get 
diluted and probably particular features of transplant 
activities may be overlooked. This would make the 
EMBMT report an important source that details imt
portant issues related to the HSCT activities and the 
specific challenges in the region. This report should 
serve as a basis for decision making on how to provide 
the necessary infrastructure, set up the best referral syst
tem and initiate support services like alternate donor 
or cord blood banking, and algorithm of management 
based on the best available options and optimal utilizat
tion of services without denying the patient the need for 
new modalities in transplant procedures.9t14
In previous reports15t22 from the region, it was clear 
that the chance of finding a matched sibling donor is 
probably one of the highest in the world,23 making 
sibling donors the overwhelmingly best available opt
tion for the majority of patients. The relatively younger 
age of patients and donors is also of importance. On 
the other hand, many challenges are frequently faced, 
like the relatively high rate of cytomegalovirus (CMV) 
positivity, hepatitis C virus (HCV), hepatitis Bt virus 
(HBV), and tuberculosis (TB) infections.9 
In some countries, the choice between transplantat
tion and other modalities like tyrosine kinase inhibit
tors (TKI) for chronic myeloid leukemia (CML) or 
antithyocyte globulin (ATG) for severe aplastic anemia 
(SAA) is tipped in favor of transplantation as the best 
“available” costteffective option.15t16 
The first detailed EMBMT report24 showed an 
impressive increase over many years in the number of 
centers and number of HSCT in the region. The mat
jority of allotHSCT had been done for proportionately 
younger patients and the most common indications 
were acute leukemia, bone marrow failure syndromes, 
thalassemia, and inherited immune deficiencies. For aut
tologous HSCT (autotHSCT), the most common int
dications were myeloma and lymphomas in adults and 
solid tumors, especially neuroblastoma in children. The 
report also stressed the marked variability in the rate 
and trends in utilization of HSCT amongst EMRO 
countries and between the EMBMT centers and globt
ally. In the current report, recent trends and activities in 
2008 and 2009 will be discussed with a special focus on 
a comparison to contemporary trends from EBMT.13 
Additional details of numerical performance of allot
HSCT at large centers across the last five years will also 
be discussed.
STUDY DESIGN AND METHODS
The goal was to study the trends of transplant activit
ties in the EMRO region as reported to the EMBMT 
group in the years 2008t2009 and compare these to pret
vious trends in the region and to contemporary trends 
by EBMT.13
Organization, teams, data collection and validation 
This study was conducted by the EMBMT center with 
waived informed consent of patients. No individual 
data was uncovered by any of the investigators or the 
authors. Data was used only for collective analysis of 
trends at the center, national or regional level. This was a 
retrospective survey among all transplant teams (n=14) 
that are members of EMBMT and known to the int
vestigators. One team can be working at more than one 
center and a center may be served by two teams. For 
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transplant by indication, only the first transplant was 
reported to avoid retreporting. After data entry and 
computation, a review of the final draft by the referring 
team was done before the final analysis and graph plott
ting. Centers with less than 5 transplants/year for the 
last 3 years were not included. Moreover, transplants 
done to patients who cross borders outside the relevant 
country were not reported. Further details of reporting 
are already published in a previous EMBMT report.24
Data was validated through a written survey form 
submitted by each transplant center followed by vert
bal communication between the central offices of the 
EMBMT and the reporting teams. Collective and cent
tertbased data were further discussed with the relevant 
teams on EMBMT business meeting in 2010, and then 
a draft of the final report was sent to each center before 
final publication. 
The main outcome measures included cumulative 
number of transplants, types of transplants (autologous 
vs. allogeneic), types of conditioning such as myeloabt
lative conditioning (MAC) vs. reduced intensity cont
ditioning (RIC) vs. others, and study of the trends in 
indications with a special focus on hemoglobinopathies, 
severe aplastic anemia (SAA), inherited bone marrow 
failure syndromes and leukemias, among others. 
Definitions 
Team size is defined according to previous reports1,25 as 
the number of first HSCT for patients transplanted in 
the relevant year.
Team density is defined as the number of transplant 
teams per 10 million inhabitants and is computed for 
each country and for the whole region. 
Transplant number and sources: The current report 
is focused on the number of patients transplanted for 
the first time. Additional transplants were further ret
ported under each disease category, whether they were 
a second transplant in a pretplanned double transplant, 
e.g., autologous followed by RIC allogeneic transplant 
or a tandem (double autologous) transplant. 
Transplant rate is the number of transplants pert
formed within the borders of that country per 10 milt
lion inhabitants as previously defined.25 Transplant rate 
refers to the number of transplants in a given country 
compared to its own population. No adjustments were 
made for those who crossed borders to receive transt
plants outside their country. Population data were obt
tained from the US census office (http://www.census.
gov).26 
Rettransplant is defined as unplanned HSCT for 
relapse or rejection.
Stem cells source: information on stem cell source 
was reported as bone marrow (BM), cord blood (CB) 
and peripheral blood (PB). Any transplants with a 
combination of stem cell source that included CB were 
reported as CBT; BM and PB combinations were ret
ported as PB. 
Conditioning: MAC and RIC were reported by each 
team following the recently published definitions.14 For 
those with incomplete details or who did not appear to 
the reporting team to fit into a clear category were ret
ported as unknown or others, respectively. 
Statistical analysis
 Descriptive data analysis was performed with a focus 
on 2008 and 2009. EBMT practice guidelines were 
used for disease indications. The transplant rate was 
calculated according to the number of transplants by 
disease indication in relation to the mean population 
census (http://www.census.gov)26 for the correspondt
ing period 2008t2009. The above descriptive definit
tions and calculations in transplant rate, team size and 
team density were also applied.
RESULTS
Survey outcome and participating teams
A total of 14 reporting teams from 10 countries ret
ported their data (100% return rate) for the years 
2008t2009. These countries in alphabetical order 
were: Algeria, Egypt, Iran, Jordan, Lebanon, Saudi 
Arabia, Morocco, Oman, Pakistan, and Tunisia. Teams 
from Algeria reported their data for the first time to 
EMBMT (Table 1). The corresponding addresses are 
listed also in alphabetical order in Appendix 1. Six 
countries also report to EBMT and include Algeria, 
Iran, Jordan, Lebanon, Saudi Arabia and Tunisia. All 
teams performed both allogeneic and autologous transt
plantations with marked variation in the rate of each of 
these modalities (Figure 1). 
There was a significant improvement in reporting 
details of transplants compared to 2007 (Table 2). For 
example, the details of conditioning were reported as 
unknown/others in 41.8% in 2007, compared to 4.4% 
in 2008 and 5.6% in 2009. Meanwhile, the allogeneic 
stem cell source was reported as unknown in 7.9% in 
2007 and became 0% in both 2008 and 2009.
The total number and the proportions of all indicat
tions of transplants per each country are collectively ilt
lustrated in Table 1 and Figure 1 and varied greatly bet
tween countries (13 to 389 in 2008, 15 to 366 in 2009). 
The mean rate of HSCTs for the whole region for the 
period of observation was 29.2 and it was <25 for 3 
countries, 25t50 for 2 countries, 51t100 for 2 count
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tries and 101t200 for the remaining 3 teams (Table 3, 
Figure 2).
Trends of transplantation compared to the previ-
ous report in 2007
Overall, there was a trend towards an increased total 
number of transplants (both allot and autotHSCT) 
across the years 2008t2009 compared to 2007, (Table 
2, Figure 3). In 2008, the total number of transplants 
was 1286 (816 allogeneic, 470 autologous) with an int
crease of reporting by 17.2% compared to 2007 (total 
1097).24 This was attributed mainly to the addition 
of Algeria. However, even without Algeria, the group 
showed a marginal increase of 5.1%. In 2009, the total 
number reached 1322 (839 allogeneic; 483 autologous) 
with an increase of 2.8% compared to the previous year. 
AllotHSCT remained the predominant type in the ret
gion (62% in 2007, 63% in both 2008 and 2009). As 
shown in Table 2, the trend of change was consistent 
with an increased rate across all indications except a 
trend towards a reduction in allogeneic transplants for 
CML and in autotHSCT for acute leukemias.
Trends in allogeneic and autologous transplantation
All centers, except one, performed both Allot and Autot
HSCT and the majority of the cord blood transplants 
were performed by 2 centers although 7 did at least one 
CBT in 2 years.
Also, RIC trend was towards an increase, yet modt
est, across 2007t2009 in both absolute number and 
in ratio. Although, the ratio of cord blood utilization 
remains nearly the same in 2008t2009 (~5%), it int
creased from 28 (4.4%) in 2007 to 42 (4.9%) in 2009. 
Other peculiar trends are also explained in the relevant 
sections of the study. The main indications for HSCT 
in 2008 and 2009 in comparison to the previous year 
are listed in Table 2 and their distribution is illustrated 
in Figures 4-7.
Allogeneic transplantation 
A total of 1700 stem cell sources were used for 1655 
transplant indications in 2008 (816 cases) and 2009 
(839 cases). There was a nontsignificant increase 
(2.8%) in the number of transplants in 2009 compared 
to 2008. However, as shown in Table 2 and Figure 3, 
2008 witnessed an increase by 19.3% when compared 
to 2007 (total 684), largely due to the addition of a new 
team, in addition to an increase in the rate of transt
plants (5.4%).
Indications of allogeneic transplantation by disease 
There was a marked variation in the indications among 
centers. More than half of allotHSCT were done for 
clonal hematologic disorders (465; 57% in 2008; 466 
55.5% in 2009), mainly acute leukemia (372; 45.6% in 
2008 and 360; 42.9% in 2009) with more cases (223; 
27% in 2008, 217; 26% in 2009) of AML than for ALL 
(149; 18% in 2008 and 143; 17% in 2009). There was 
a trend for transplanting AML cases in CR1 (78% of 
cases across both years) which did not differ from 2007 
(77%) (Figure 8). The same trend was also observed 
in ALL but with a lesser degree (60% in CR1 in 2007, 
53% in 2008 and 61% in 2009) (Figure 9).
CML cases (Figure 10) represented a small minort
Table 1.  Number of HSCTs in EMRO per each EMBMT country in 2008-2009.
Country
2008 2009 Total  
2008-9 %Allo Auto Allo Auto
Algeria* 95 38 100 76 309 11.8
Egypt 103 25 110 12 250 9.5
Jordan* 49 41 38 48 176 6.7
Iran* 247 142 249 117 755 28.9
Saudi 
Arabia* 173 78 179 75 505 19.3
Lebanon* 16 60 25 53 154 5.9
Morocco 0 20 2 20 42 1.6
Oman 9 4 15 0 38 1.4
Pakistan 73 9 69 15 166 6.3
Tunisia* 51 53 52 67 223 8.5
Total 816 470 839 483
Overall 1286 1322 2608
HSCT: Hematopoietic stem cell transplants; Allo: Allogeneic HSCT; Auto: Autologous HSCT; *Also report to EBMT.
Figure 1. Number and proportions of total HSCTs per each EMBMT country in 2008-2009.
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ity (41; 5% in 2008; 45; 5.4% in 2009) and remained 
nearly stable over the 2tyear period. However, there was 
a significant increase in the number of patients transt
planted beyond first chronic phase (3 cases in 2008 and 
13 in 2009). 
For MDS, there were more transplants (n=36; 
4.3%) performed in 2009 than in 2008 (n=23; 2.8%) 
with a significant increase (57%) (Table 2). Only 7 
(<1%) transplants had been performed for MPNs in 
2008 and 6 (<1%) performed in 2009. Lymphomas 
(HD, NHL) and multiple myeloma represented a relat
tively small minority (22; 2.7% in 2008 and 19; 2.3% in 
2009); nearly half of them were high grade/or aggrest
sive lymphomas.
Bone marrow failure syndromes represented the 
second largest single indication after leukemias in both 
2008 (165; 20.2%) and in 2009 (166; 19.8%) and int
cluded acquired SAA (131; 16.1% in 2008; 133; 15.9 % 
in 2009) and congenital bone marrow failure syndromes 
(31; 3.8 % in 2008 and 27; 3.2 % in 2009), amongst 
others (Figure 4, 5). Hemoglobinopathies (mostly Bt
thalassemia) were the third most common indication 
for allotHSCT in both 2008 (124; 15.2%) and 2009 
(131; 15.6%) (Figure 4, 5). These were largely contribt
uted by Iran (63; 7.7 % in 2008; 73; 8.7 % in 2009) and 
Pakistan (29; 3.5 % in 2008 and 20; 2.4 % in 2009), alt
though other centers also performed a significant numt
ber of such cases (Saudi Arabia 10 and 9 cases; Egypt 8 
and 10 cases in 2008 and 2009, respectively). 
Of particular mention is the group of recipients 
with primary immunodeficiency syndrome (39; 4.8% 
in 2008 and 51; 6.1% in 2009) and those with inherited 
metabolic disorders (11 in 2008 and 14 in 2009) like 
osteopetrosis and other metabolic disorders.
Autologous stem cell transplantation
967 autologous stem cell sources were utilized for a total 
of 953 disease indications in the survey period (470 in 
2008 and 483 in 2009), compared to 413 disease indit
cations reported in 2007, with a progressive increase in 
absolute number by 57 (13.8%) in 2008 and 13 (2.7%) 
in 2009 (Table 2). The increase in 2008 was largely due 
to increased reporting after the addition of two teams 
from Algeria (n=38), but the increase in 2009 was real.
Nearly all the indications were for clonal disorders 
(456; 98.5% in 2008 and 479; 99.2% in 2009). For the 
year 2008, the most common indications were plasma 
cell disorders—mostly myeloma—in 158 (33.6%), folt
lowed by HD 121 (25.7 %) and NHL 112 (23.8%). 
Solid tumors accounted for 41 (8.7%); the most comt
mon solid tumor being neuroblastoma (29; 6.1%), 
although others like germ cell tumors were also pert
Table 2.  Overall HSCT activities in 2008-2009 compared to 2007 in EMRO region as 
reported to EM-BMT by indications, stem cell source, and type of conditioning. 
Total 2007 2008 2009
Allo-HSCT  vs. Auto-HSCT 684 vs. 413 816 vs. 470 839 vs. 483
Main Indications of Allo-HSCT  684 816 839
     Acute leukemia 289 (42%) 372 (45.6%) 360 (42.9%)
          Acute myeloid leukemia 172 (25%) 223 (27%) 217 (26%)
               CR1 vs. >CR1 133 (19%) vs. 38 (6%)
175 (20%) vs. 
48 (6%) 
170 (20%) vs. 
47 (6%)
          Acute lymphoblastic 
          leukemia 109 (17%) 149 (18%) 143 (17%)
               CR1 vs. CR2 65 (9%) vs 54 (8%)




     Chronic myeloid leukemia 60 (8.7%) 41 (5%) 45 (5.4%)
          CP-1 vs. >CP-1 55(8%) vs. 5 (<1%)
38 (4.4%) vs. 
3 (0.3%)
32 (3.8%) vs. 
13 (1.5%)
     Myelodysplastic syndrome 39 (9.4%) 23 (2.8%) 36 (4.3%)
     Myeloproliferative disorders 2 (0.4%) 7 (<1%) 6 (<1%)
     NHL 7 (1.7%) 10 (1%) 10 (1%)
     BM failure (all) 106 (15.5%) 165 (20.2%) 166 (19.8%)
     Hemoglobinopathies 102 (15%) 124 (15.2%) 131 (15.6%)
     Immune deficiency 42 (10.2%) 39 (4.8%) 51 (6.1%)
Indications of Auto-HSCT 413 470 483
     Plasma cell disorders 
     (including myeloma) 110 (26.6%) 158 (33.6%) 187 (38.7%) 
     Hodgkin’s disease 128 (31%) 121 (25.7%) 135 (27.9%)
     Non-Hodgkin’s lymphoma 103 (24.9%) 112 (23.8%) 95   (19.7%)
     Solid tumors 27 (6.5%) 41 (8.7%) 42    (8.6%)
          Neuroblastoma 16 (3.9%) 29 (6.1%) 26 (5.3%)
     Acute myeloid leukemia 42 (10.2%) 28 (5.9%) 19 (3.9%)
     Others 3 (1%) 10 (2.1%) 5 (1%)
Conditionings for Allo-HSCT* 684 775 791
     Conventional 347 (50.7%) 658 (84.9%) 645 (81.5%)
    Reduced intensity 
    conditioning 51 (7.4%) 83 (10.7%) 101 (12.8%)
     Unknown/other 286 (41.8%) 34 (4.4%) 45 (5.6%)
Stem Cell source for Allo-HSCT 647 837 863
     Bone marrow-related 156 (24.8%) 232 (27.7%) 254 (29.4%)
     Peripheral blood-related 408 (64.8%) 535 (63.9%) 541 (62.7%)
     Cord blood 28 (4.4%) 41 (4.9%) 42 (4.9%)
     Matched unrelated donor 1 (0.1%) 1 (0.1%) 0 (0%) 
     PB+BM/BM+CB NA 27 (3.2%) 26 (3%)
     Unknown 54 (7.9%) 0 (0%) 0 (0%)
Stem cell source for Auto-HSCT 413 474 495
     Bone marrow-related 6 (1.5%) 21 (4.4%) 13 (2.6%)
     Peripheral blood-related 407 (98.5%) 452 (95.6%) 481 (97.4%)
     Unknown 1 (0%0 1 (0%)
Auto-HSCT: autologous HSCT; Allo-HSCT: allogeneic hematopoietic SCT;  CR1: first complete remission;  >CR-1: beyond 
CR1;   CP-1: first chronic phase;  >CP-1: beyond CP-1;   Others: autoimmune disorders , germ cell tumors, inherited 
metabolic disorders 
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formed (7; 1.4%). The main indications in 2009 were 
nearly the same: myeloma in 187 (38.7 %), HD in 135 
(27.9 %), NHL in 95 (19.7%) and solid tumors at 42 
(8.6%). A recognizable progressive increase was seen in 
the absolute number and percentage of myeloma transt
planted over the last 3 years (110; 26.6% in 2007, 158; 
33.6% in 2008 and 187; 38.7% in 2009). 
 Compared to myeloma, Hodgkin disease showed 
quite a similar, yet slightly lesser increase (11.6%) over 
the study period. The remarkable increase in reportt
ing solid tumors was noticed mainly in 2008 with a 
51.8% increase that was attributed to both the addit
tion of Algeria and to an actual increase by the other 
countries. However, 2009 did not witness a signifit
cant increment (only 2.5%). About twotthirds of the 
transplants for solid tumors (71% in 2008 and 61% in 
2009) were performed mainly for neuroblastoma and 
mainly for pediatric/adolescent patients. On the cont
trary, NHL cases decreased from 2008 (112; 23.8%) 
to 2009 (95; 19.6%), representing a relative decrease 
by 15.1%. Although the majority were of aggressive 
types like diffuse large cell lymphoma (DLBCL) and 
prolymphocytic leukemia (PLL), other forms were 
also performed. 
There was also a progressive decline both in absot
lute number and percentage of acute myeloid leukemia 
(AML) during the observation period (28; 5.9% in 2008 
and 19; 3.9% in 2009) while no center performed Autot
HSCT for acute lymphoblastic leukemia (ALL) (Table 
2, Figure 6, 7). The decline in AML autottransplanted 
has not been limited to the last 2 years but started even 
earlier (n=41; 12.4% in 2006, n=42; 10.2% in 2007). 
However, autotHSCTs for AML were almost all done 
in CR1.
Literally, no single case of breast cancer or renal 
cell carcinoma was performed during the same period. 
There was a marked variation between countries in the 
utilization and overall rate of autotransplants (between 
4ttot142 in 2008 and 0ttot117 in 2009), with a median 
of 53 in both 2008 and 2009. 
By stem cell source
A total of 1700 allogeneic stem cell sources were used 
for a total of 1655 disease indications (837 in 2008 and 
863 in 2009) (Figure 11). Bone marrow (BM) was the 
only source utilized in 232 (28%) in 2008 and in 254 
(29%) in 2009. Although there was marked variability 
in the rate of utilization of stem cell sources among cent
ters, peripheral blood stem cell (PBSC) alone was the 
predominant stem cell source (535; 64% in 2008 and 
541; 63% in 2009) especially in acute leukemia beyond 
first complete remission, MDS and CMLtAP/BC. The 










Algeria* 309 34.1 45.3
Egypt 250 78 16
Jordan 176 6.15 143
Iran* 755 75.5 50
Saudi 
Arabia* 505 25.2     100
Lebanon* 154 4.1 187
Morocco 42 31.2 6.7
Oman 38 2.9 65.5
Pakistan 166 179.5 4.6
Tunisia* 223 10.35 107
Total 2608 447 n= 29.2
n: mean number of transplant per 10 million *Also report to EBMT. 
**According to the mean population census 2008-9 ( http://www.census.gov)26
Figure 2. Transplant rate (per 10 million population) of EMBMT 
countries 2008-2009.
Figure 3. Trend in autologous and allogeneic HSCT in EMRO region as reported to 
EMBMT group in 2008-2009 compared to 2007.
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only disease indications with more bone marrow source 
than peripheral stem cell donors are bone marrow failt
ure syndromes (SAA) and congenital disorders. 
Regarding donor types, the most common was relatt
ed matched donors. Cord blood (CB) as the only source 
was used in 41 (5%) in 2008 and in 42 (5%) in 2009. 
Overall, cord blood sources were used mainly for pedit
atric patients. Combined CB+BM /PBSC+BM were 
used in 27 (3%) cases in 2008 and in 26 (3%) cases in 
2009. A single case of matched unrelated donor and 
another single case of haplotidentical T celltgraft were 
used in the 2tyear period. For cord blood transplant
tation, the most common indications were inherited 
immune deficiency and inborn errors of metabolism, 
mostly in pediatrics and the vast majority had been pert
formed in Saudi Arabia and Jordan.
For the autotHSCT, PB was the most common 
source utilized both in 2008 (452; 95%) and in 2009 
9481; 97%). Overall, 95% of stem cell sources for AML 
patients were allogeneic and 5% were of autologous 
source, while all sources used for CML, MDS and ALL 
were allogeneic. There was a trend for more utilization 
of BM source in benign hematologic disorder and cont
genital diseases compared to malignant disorders.
Conditioning 
For allogeneic HSCT, a total of 1566 conditioning 
regimens were reported in the 2tyear period includt
ing 1303 (83%) conventional myeloablative and 184 
(12%) reduced intensity by different protocols. There 
was a progressive increase in the absolute number and 
percentage of utilization of RIC in the region over the 
last few years most notably during the last 2 years (51; 
7.4 % in 2007, 83; 10.7% in 2008 and 101; 12.7% in 
2009) (Table 2, Figure 12). As indicated in Table 2, it 
is clear that there was an improvement in the accuracy 
of reporting and completing of details of conditioning 
as the reported number of unknown conditioning/otht
ers decreased to 4.4% and 5.6% only over the 2tyear 
observation period .The minor difference between the 
total number of allotHSCT indications and conditiont
ing reported is likely due to some immune deficiency 
cases where conditioning may not be required. Because 
the information collected is generic, there were no furt
ther details of the disease distribution within each type 
of conditioning.
Novel Cellular Therapies
Donor lymphocyte infusion (DLI) is still underutit
lized in the region. In 2008, only 7 cases were reported 
(total number of sessions unknown) representing only 
8.3% of reduced intensity conditioning and only 1% 
of all conditionings for allogeneic stem cell transplant. 
The corresponding number for the year 2009 was even 
lower at 3 cases (3% of RIC and <0.5% of all condit
tioning regimens delivered). Two cases of autotHSCT 
for critical limb ischemia were performed (one with PB 
and one with BMtHSC) in 2009 at a single institution 
Figure 5. Absolute number and relative proportions of indications for Allo-HSCT in EMRO 
region as reported to EMBMT in 2009. 
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; 
MDS: myelodysplastic syndrome; MPD: myeloproliferative disorders; Hb/ Thal: hemoglobinopathies 
(thalassemia); NHL: non-Hodgkins lymphoma; BM failure: bone marrow failure syndromes; PID 
(SCID): primary Immune deficiencies including severe combined immune deficiency diseases
Figure 4. Absolute number and relative proportions of indications 
for Allo-HSCT in EMRO region as reported to EMBMT in 2008.  
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: 
chronic myeloid leukemia; MDS: myelodysplastic syndrome; MPD: 
myeloproliferative disorders; Hb/Thal: hemoglobinopathies (thalassemia); 
NHL: non-Hodgkins lymphoma; BM failure: bone marrow failure 
syndromes; PID (SCID): primary immune deficiencies including  severe 
combined immune deficiency diseases
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EMRO region as reported and reflected in the activities 
of EMBMT teams in 2 years, 2008t2009. Although it 
is just the second report, it confirms and highlights imt
portant developments and peculiar practices.9,24
Many of the EMRO countries are developing count
tries where stem cell transplant technology has started 
at single centers considered as “national” centers. It 
seems to be approved and supported by governmental 
and nontgovernmental bodies to help satisfy some of 
the sore needs of the region for such an economically 
intense procedure that depends on very intricate infrat
structure and multidisciplinary activities.15
It is clear that the group is growing and new activit
ties are added to the current report by the joining of 
Algeria. However, the team density in the region is still 
far less than the status in Europe (0.3 vs. 7.6) (Table 
4) indicating a sore need for further increase in human 
resources to satisfy the region’s increasing needs of such 
a high technology procedure. The trend of progrest
sive increase in both allogeneic and autologous HSCT 
(Figure 3) is clearly noticed over the study period and 
confirms what was reported previously in the 2007 act
tivities’ report.24 Nevertheless, the stand of allogeneic 
HSCT is still dominant (63.5% in 2009) (Table 4) 
which is opposite to the trend in Europe where Auto 
HSCT continued to outnumber allotransplants (59% 
vs. 41%).13 Such dominance of AllotHSCT in EMRO 
and dominance of AutotHSCT in Europe could be att
tributed to the relatively older populations transplantt
ed in Europe with higher proportions of lymphoid 
and plasma cell disorders requiring AutotHSCT13 in 
contradistinction to a relatively younger patients in 
EMRO with a larger need for allogeneic transplants.9 
Many other important differences also exist and may 
be explained by socioeconomic, prevalence of relevant 
diseases or even the demographic features of the target 
population of patients, but all mandate prospective colt
laboration and exchange of experience between study 
groups and registries.28 Such a remarkable difference 
highlights the important variation in practices between 
world regions and illustrates the importance of key 
regional reports in the field for better assessment and 
decision making. Of particular interest is the observat
tion that countries like Morocco, Tunisia and Lebanon 
are doing Autot HSCT more than AllotHSCT which 
parallels the practice in Europe.
Meanwhile, in AllotHSCT, MUD is still markt
edly underutilized (n=1; 0%) ( Figure 11), compared 
to the overwhelmingly increased rate in Europe (46% 
of allotSCT in 2009)13 which reflects many facts on 
the ground. First, disease distribution and indication 
with higher rates of indications for BM failure synt
Figure 6.  Absolute number and relative proportions of indications for Auto-HSCT in 
EMRO region as reported to EMBMT in 2008. 
PCD: plasma cell disorders including multiple myeloma, NHL: Non-Hodgkin lymphoma; HD:Hodgkin’s 
disease; CLL/PLL: chronic lymphocytic leukemia/prolymphocytic leukemia; Breast CA:breast 
cancer; GC:Germ Cell tumors; AID:autoimmune diseases; AML: acute myeloid leukemia; ALL: acute 
lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; MPD: 
myeloproliferative disorders; Other ST: other solid tumors.
(KFSHRC), in a research protocol, but were not int
cluded in the statistical analysis as detailed information 
on the procedures was substantially limited. 
DISCUSSION
The present data reflect the status of HSCT in the 
Figure 7. Absolute number and relative proportions of indications for Auto-HSCT in 
EMRO region as reported to EMBMT in 2009. 
PCD: plasma cell disorders including multiple myeloma, NHL:  non-Hodgkins lymphoma; HD: 
Hodgkin’s disease; CLL/PLL: chronic lymphocytic leukemia/prolymphocytic leukemia; Breast Ca: 
breast cancer; GC: germ cell tumors; AID: autoimmune diseases; AML: acute myeloid leukemia; ALL: 
acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; 
MPD: myeloproliferative disorders
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dromes and hemoglobinopathies in the EMRO region 
(35.4%) compared to the EBMT countries (8%).13t18 In 
such conditions, sibling donors represent the best fit.24 
Second, the better availability of MRD (68%) in the 
EMRO region due to better ethnic homogeneity and 
consanguinity which perhaps leads to better clustering 
and retention of HLA antigens and also due to larger 
size of families.23 Third, the cost and logistics of MUD 
transplant are resourcestconsuming that it would be 
very difficult for many centers to cope with the escalatt
ing needs while facing such very costtintense procedure 
for a small minority.29 Such difficulties would be cont
siderably overcome by initiating locotregional donor 
registries that would help find a suitable donor from the 
same ethnic group at lower costs. 
For AllotHSCT, myeloablative conditioning ret
mained the predominant type preparation compared to 
RIC (12.8% in 2009) ( Figure 12) and probably fits the 
optimal needs to achieve disease eradication, reducing 
rate of relapse and allowing good stable engraftment in 
a relatively young patient population.9 In contrast, the 
EBMT survey13 for the year 2009 demonstrated that 
RIC was utilized in 39% of all AllotHSCT, and has 
been reported to be as high as 71% in some European 
countries.28,29 Nonetheless, the trend of steady, yet slowt
ly, increasing rate of RIC may probably suggest recent 
broadening of target population and indications and 
parallels the overall international trend of increased utit
lization.27,30 The great variability in rate of utilization of 
RIC among centers could not be explained. 
The lack of guidelines in use of DLI, limited availt
ability of resources for further curative intents in case 
of relapse or the preference of a second transplant may 
be a plausible explanation for the markedly low rate of 
such a viable modality. It could also be, though partly, 
linked to the lower rate of RIC.13
Status of transplants in specific diseases
 The main indications for allogeneic HSCT were acute 
leukemias, bone marrow failure syndromes and hemot
globinopathies, at 1318 (79.6% of AllotHSCT). This 
represents a peculiar distribution reflecting not only 
the prevalence of such diseases in the region, but also 
the pressure of prioritization on the regional centers as 
most of the cases are relatively young compared to the 
west. The significantly large number of transplants for 
clonal hematologic diseases, mainly acute leukemia is 
matching with the rapidly increasing role of allogeneic 
HSCT for such disorders (Figure 4, 5). The majority 
of AML cases were transplanted in CRt1 compared to 
CRt2 and literally there were few, if any, transplanted 
in CRt3 which parallels the contemporary international 
Figure 8. Trend of allogeneic-HSCT for acute myeloid leukemia in 2008-2009 compared to 
2007 in EMRO region as reported to EMBMT. 
AML: acute myeloid leukemia; CR1: first complete remission; >CR1: beyond first complete remission. 
Numbers posted are absolute numbers.
Figure 9. Trend of allogeneic-HSCT for acute lymphoblastic 
leukemia in 2008-2009 compared to 2007 in EMRO region as 
reported to EMBMT.  
ALL: acute lymphoblastic leukemia, CR1: first complete remission; >CR1: 
beyond first complete remission. Numbers posted are absolute numbers.
Figure 10. Trend of allogeneic-HSCT for CML in 2008-2009 
compared to 2007 in EMRO region as reported to EMBMT. 
CML: chronic myeloid leukemia; CP-1: first chronic phase; >CP-1: beyond 
first chronic phase. Numbers posted are absolute numbers. 
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trends especially in the region’s a relatively young poput
lation (Figure 8).9,31t32 It may reflect not only tightened 
prioritization but also the incorporation of many progt
nostic and risktstratification tools in upfront assesst
ment of such a grave disease. Such a situation creates a 
sore need for further expansion with stronger support 
from both governmental and none governmental if such 
ultrathigh risk cases were to be transplanted.
With the development of many comprehensive pet
diatric and adult programs for management of ALL 
patients in the region, it has become clear that many pat
tients had been stratified upfront to receive AllotHSCT 
in CR1 (10%) (Figure 9), which is matching in many 
ways the common practice as reflected in the EBMT 
and CIBMTR data.33t35 This is further illustrated in the 
Figure 11. Proportions of Allo-HSCT sources in EMRO region as 
reported to  EMBMT in  2008-2009.  
Related PB: related peripheral blood HSCT; Related BM: related bone 
marrow HSCT; CBT: cord blood HSCT; PB+BM/CB+BM: peripheral blood 
plus bone marrow/ cord blood plus bone marrow; Haplo-TCD: haplo-
identical -T cell depleted HSCT; MUD: matched unrelated donor HSCT. 
Figure 12. Trends in the use of reduced-intensity and conventional conditioning in EMRO 
region as reported to EM-BMT 1984-2009. 
RIC: reduced conditioning regimens; UK: unknown. Numbers posted are absolute.   
impressive lack of utilization of AutotHSCT for ALL, 
which is probably based on the relatively recent results 
of large randomized studies showing no significant bent
efit of autologous SCT compared to chemotherapy in 
ALL patients with no donors.35
Two important phenomena are worth discussing in 
relation to CML. First, the noticeable progressive det
cline in the overall number and proportion of transplant
tation for CML patients over the last 5 years (n=103; 
15% in 2006, n= 45; 5% in 2009) (Figure 10). Such 
trend was due to the positional success of TKI therapy 
in replacing transplantation as a first line of therapy.
This same era has witnessed also a trend of an int
creased ratio of transplants for accelerated and blastic 
crisis CML cases that reached to a peak in 2009 when 
nearly 30% of CML cases were advanced phasetCML 
compared to only 5t8% in the years 2005t2007. A ret
cent survey by EBMT demonstrated that the number 
of AllotHSCTs performed in CML patients beyond 
first chronic phase exceeds the number of AllotHSCT 
performed in first CP.36 Such a trend may be related to 
the ability of achieving a second chronic phase in some 
patients with the use of second generation TKI therapy 
without the need for intense chemotherapy induction. 
The transplantation outcome in advanced phase 
CML patients is basically in line with earlier observat
tions that the best long term survival results in blast 
crisis are achieved by allo SCT and that most long term 
survivors in blast crisis received an allotHSCT, mostly 
in second CP.37,38
Benign hematologic disorders like aplastic anemia, 
congenital bone marrow failure syndromes and hemot
globinopathies represented the second largest group of 
indications in the region which contrasts very well with 
the temporal practice in Europe where all benign disort
ders represent only 8% of allotransplants,13 compared 
to 35% in EMRO in 2009. For thalassemia, HSCT is 
probably more cost effective with worth risktbenefit rat
tio than chronic chelation and transfusion program in 
many countries in the region with very limited resourct
es and heightened compliance issues.15 It is mostly pert
formed at centers where the prevalence of the disease 
represents a national problem, like in Egypt and Iran.15,22 
Risk stratification based on Pesaro criteria is applied by 
most centers to prioritize low and intermediate risk 
groups for transplantation.15 In both Thalassemia and 
SAA, bone marrow is the preferred source of stem cells, 
explaining the relatively higher proportion of BM as a 
source of stem cells. Practices and data on inherited and 
acquired bone marrow failure syndromes represent one 
of the largest experiences that are previously published 
and illustrate a diverse distribution in the region.16,39t41
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Table 4. Comparison between Trends in HSCT between EBMT and EMBMT in 2009.
EBMT report 2009 




(including the 6 
affiliated EMRO 
countries)
Number  of teams 647 14
Countries 48 10
Average Teams/country 14  1.4
Team Density /10 M inhabitant 7.6* 0.3*
Rate of HSCT /10 M population 467 28.7
Total first Transplants 28 033 1322
     Allo-HSCT 11 442 (41%) 839 (63.5%)
     Auto-HSCT 16 591 (59%) 483 (36.5%)
Main  indications of HSCT
     Non-malignant 5.5% 27.9%
     Malignant disorders 95% 72.1%
          Leukemias (% of total)
8752 (31.2%)
Allo; 8022(92%) vs. 
Auto, 730 (8%)
426 (32.2%)
Allo, 407 (95.5%) vs. 
Auto, 19(4.5%)
          Lymphomas/myeloma
16 196 (57.7%)
 Allo, 1901 (12%) vs. 
Auto, 14 295 (88%)
427 (32.3%)
Allo, 10 (2.3%) vs. 
Auto, 417 (97.7)%   
          Solid tumors
1454 (5.2%)
     Allo, 6% vs. 
Auto, 94%
    42 (3.2%)
     Auto, 100%
Conditionings for allo-HSCT NA        791
     Conventional 61% 645 (81.5%)
     Reduced intensity 
     conditioning 39% 101 (12.8%)
     Unknown/others 0% 45 (5.6%)
Stem cell source for allo-HSCT 11 442 863
     Bone marrow 2 569 (22%) 254 (29.4%)
     Peripheral blood 8 119 (71%) 541 (62.7%)
     CBT 754 (7%) 42 (4.9%)
Donor source in allo-sources 11 442 863
     Identical sibling PB/BM 4 856 (42%) 821 (95.1 %%)
     Unrelated donor HSCT 5 167 (45%) 0 (0%)
     Cord blood HSCT 701 (6%) 42 (4.9%)
     Other family 702 (6%) NA
Stem cell source for autologous
     Bone marrow 1% 2.6%
     Peripheral blood 99% 97.4%
NA: not available; Auto: autologous HSCT; Allo: allogeneic hematopoietic SCT; *estimated based on 2009 census26
It is comforting to observe that AutotHSCT is rist
ing as the preferred modality in the management of 
multiple myelomas and lymphotproliferative disorders 
in spite of the relatively younger age of targeted patients 
and it appears to match the current world wide pract
tices that are based on prospective studies.42t46 This is 
closely similar to the EBMT13 in myeloma (38.7% % 
of all autotHSCTs in EMBMT and 43% in EBMT 
in 2009). However, AutotHSCT is nearly the only 
modality of transplantation (97.7% ) for lymphomas 
and myeloma in EMBMT while a significant minority 
(12%) underwent allotHSCT in Europe for the same 
year (Table 2, 4).The recognizable progressive increase 
in the number and rate of AutotHSCT for myeloma 
across the years 2007t2009 (110; 26.6%, 158; 33.6% 
and 187; 38.7%) is a natural product of improved pert
formance of the teams, advancing technologies and 
probably also the ability to achieve meaningful remist
sion status (VGPR or CR) with the advent of the new 
modalities of therapy.42 Nonetheless, such a remarkably 
higher rate of AutotHSCT would have not been att
tained without improved orientation about the import
tant role of HSCT in improving outcome of such dist
ease as outlined in recent practice guidelines.43,44
The trend of larger proportion of HD (27.9%) in 
the EMRO region compared to EBMT13 (11%) with a 
completely opposite trend with NHL (19.6% vs. 32%) 
(Table 2), is largely due to the agetdependent prevat
lence of NHL and larger use of RIC and DLI in the 
West and the relatively younger population with more 
prevalent HD in the EMRO region. Amongst solid tut
mors, neuroblastoma remains the most common type 
treated by autotHSCT by pediatric teams.46 Such apt
proach is based on important positional studies that 
have made autotHSCT an important viable option for 
long term cure in high risk patients.47
Without both cost effective comparative analysis and 
outcome data analysis, it would be very misleading to 
depend only on crude data collection for decision makt
ing, especially in selecting transplantation compared to 
other doset and costt intense modalities available in the 
region. It would also be better to adjust for the patient 
mix and other clinicotbiological features of transplanted 
patients when comparing between countries and global 
EMBMT data.
Numerical performance of allogeneic transplants 
by large centers 
The current report also recognizes considerable variat
tion amongst centers in the rate of transplants per year 
and per 10 million of the population, as well as in the 
distribution of indications. Operational factors may be 
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due to substantial variation in acceptance among cent
ters and across years, center capacity, team size, as well 
as national rate and burden of diseases.48 Shortage of 
well qualified transplant physicians and nurses may 
be an impending challenge that is underestimated and 
contribute significantly to such stagnation.49
Numerical performance in this study is meant to 
measure only the number of AllotHSCTs performed 
by the centers in any year, although it may also be sugt
gested by parameters including the rate of increase in 
the number of transplants, the increased spectrum 
of indications, and the diversity in the types of transt
plants as well as the conditioning regimens. It is clear 
that larger centers with >50 transplants/year (Table 1) 
have reached a plateau of their numerical performance 
over the last 5 years which could be attributed to the 
accumulated number of patients with late transplant 
complications without further expansion of the infrat
structure. Also, the slow shift towards RIC which does 
not need inpatient prolonged admission has further 
complicated the situation. Further adjustment of the 
transplant rate per year per the rising population cent
sus indicates clearly that such plateau is false and the 
actual rate is indeed slowly decreasing, if compared to 
the progressive rise of the population census creating a 
gap between the “center” rate of allogeneic transplants 
and the “national’ needs for transplants. Further details 
captured about staff resources, center facilities, cent
ter transplant bed capacity and utilization of beds by 
other nonttransplant activities like leukemia induction 
should be collected for better analysis of data and use 
for constructing a model of improvement.49,50
Because the activity survey does not provide infort
mation on the outcome or the clinicopathologic features 
of transplanted patients or their detailed management, 
it would be difficult to draw quality data assessment as 
such. It would also be impossible to compare perfort
mance based on absolute number of transplants per 
center or team. However, it may help provide a platform 
for institutional or regional health care planning. In 
particular, the centertbased capacity data may represent 
the first descriptive analysis suggesting the sore need 
for expanding HSCT availability either by expansion 
of the current centers, opening new centers or changing 
the module of transplant.
There are prospective and progressive endeavors in 
the EMBMT group to study and work on the import
tant unmet needs in the region. Because of the relativet
ly “prioritized” eligibility in many EMBMT countries 
and literally unavailability in the remaining countries 
of the region, it would be highly imperative for the ret
sponsible bodies and governments in the region to cont
duct a survey of the number of transplants performed 
for EMRO patients outside the region as well as those 
who actually needed transplants whether transplants 
are done or not done.
On the other hand , collecting and analyzing data 
on the number of centers, transplant beds, full time 
equivalent (FTE) transplant physician positions47 and 
BMTtqualified doctors who currently do not perform 
transplants may help redistribute resources for optimal 
utilization and national costtsaving. 
It has also become clear from the current and pret
vious studies that there is a great potential for further 
optimization of transplant utilization by initiating cord 
blood bank and registry and MUD bank and registry in 
the region with an expected better matching opportunit
ties and costtbenefit ratios.
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